Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.

[1]  S. Culine,et al.  Denosumab Toxicity When Combined With Anti‐angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study , 2019, Clinical genitourinary cancer.

[2]  S. Baleato-González,et al.  Specific criteria for tumor response. , 2018, Radiologia.

[3]  R. Motzer,et al.  CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. , 2017, European urology.

[4]  K. Ahrar,et al.  Cryoablation of Bone Metastases from Renal Cell Carcinoma for Local Tumor Control , 2017, The Journal of bone and joint surgery. American volume.

[5]  T. Powles,et al.  Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[6]  S. Barni,et al.  Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? , 2015, Journal of experimental & clinical cancer research : CR.

[7]  M. Staehler,et al.  Local treatments for metastases of renal cell carcinoma: a systematic review. , 2014, The Lancet. Oncology.

[8]  T. Choueiri,et al.  Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. , 2014, European urology.

[9]  V. Torri,et al.  Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. , 2014, Future oncology.

[10]  T. Choueiri,et al.  Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. , 2014, European urology.

[11]  R. Montironi,et al.  Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside , 2014, Cancer and Metastasis Reviews.

[12]  P. Tamboli,et al.  Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted-therapy era. , 2014 .

[13]  S. Barni,et al.  Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey , 2013, PloS one.

[14]  R. Motzer,et al.  Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[15]  P. Brown,et al.  Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. , 2012, The Lancet. Oncology.

[16]  Jonathan G Goldin,et al.  Computer-aided quantitative bone scan assessment of prostate cancer treatment response , 2012, Nuclear medicine communications.

[17]  T. Choueiri,et al.  Progression‐free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy , 2011, Cancer.

[18]  J. Zucman‐Rossi,et al.  Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  A. Baur-Melnyk,et al.  Bone metastases from renal cell carcinoma: patient survival after surgical treatment , 2010, BMC musculoskeletal disorders.

[20]  M. Caraglia,et al.  The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). , 2007, Journal of experimental & clinical cancer research : CR.

[21]  C. Cannon,et al.  Patient survival after surgery for osseous metastases from renal cell carcinoma. , 2007, The Journal of bone and joint surgery. American volume.

[22]  B. Fuchs,et al.  Solitary Bony Metastasis from Renal Cell Carcinoma: Significance of Surgical Treatment , 2005, Clinical orthopaedics and related research.

[23]  J. Harrelson,et al.  Treatment of Osseous Metastases in Patients With Renal Cell Carcinoma , 2003, Clinical orthopaedics and related research.

[24]  H. Helenius,et al.  Feasibility of prolonged use of interferon‐α in metastatic kidney carcinoma , 2001 .

[25]  R. Coleman,et al.  The skeletal metastatic complications of renal cell carcinoma. , 2001, International journal of oncology.

[26]  R. Coleman Should bisphosphonates be the treatment of choice for metastatic bone disease? , 2001, Seminars in oncology.

[27]  R. Newcombe,et al.  Interval estimation for the difference between independent proportions: comparison of eleven methods. , 1998, Statistics in medicine.

[28]  R. Coleman Monitoring of bone metastases. , 1998, European journal of cancer.

[29]  G. Forbes,et al.  Radiographic manifestations of bone metastases from renal carcinoma. , 1977, AJR. American journal of roentgenology.

[30]  W. Gregory,et al.  Skeletal complications and survival in renal cancer patients with bone metastases. , 2011, Bone.

[31]  N. Kinnane Burden of bone disease. , 2007, European journal of oncology nursing : the official journal of European Oncology Nursing Society.